Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.

Oncotarget - 20 Sept 2016

Hastie Eric, Cataldi Marcela, Moerdyk-Schauwecker Megan J, Felt Sébastien A, Steuerwald Nury, Grdzelishvili Valery Z

Abstract excerpt

Vesicular stomatitis virus (VSV) based recombinant viruses (such as VSV-ΔM51) are effective oncolytic viruses (OVs) against a majority of pancreatic ductal adenocarcinoma (PDAC) cell lines. However, some PDAC cell lines are highly resistant to VSV-ΔM51. We recently showed that treatment of VSV-resistant PDAC cells with ruxolitinib (JAK1/2 inhibitor) or TPCA-1 (IKK-β inhibitor) breaks their resistance to VSV-ΔM51....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to I-kappa B Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon Type I

Share to Janus Kinase 1

Share to Myxovirus Resistance Proteins

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 27533247
DOI: 10.18632/oncotarget.11202
PMCID: PMC5308675

Genes

EPSTI1
GBP1
JAK1
XAF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.PMID 27533247Read ↗

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virusSemantic proximity Read ↗

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and SolutionsSemantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cellsSemantic proximity Read ↗

Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Semantic proximity Read ↗

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.Semantic proximity Read ↗

Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis VirusSemantic proximity Read ↗

Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.Semantic proximity Read ↗

Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy.Semantic proximity Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.